The Pharma Data

JANUARY 4, 2021

Kiromic chPD1 has shown in preclinical data to show a cytotoxic response in 9 different in vivo models with 100% long-term PFS with the induction of host memory responses. PD-1 has always been a challenge for CAR-T development. “We believe Prof. About PD-1 Check-point inhibition. Dr. Barber is a tumor immunologist.

In-Vivo 40

In-Vivo Development Big Data Immune Response 40

Drug Discovery World

NOVEMBER 9, 2023

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Croasdale-Wood will then participate in a keynote chat, interviewed by Miho.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against membrane protein targets, engineering bispecific antibodies, next-generation immunotherapies, protein stability and formulation, and protein process development.

Protein 59

Protein Antibody Engineer Scientist 59

XTalks

OCTOBER 1, 2020

And although academia and industry have often been pitted against each other in the realm of scientific discovery and development, there may be more similarities and synergies between the two than we may think. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist 52

Scientist In-Vitro Research Life Science 52